Global Viral Clearance Services Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than 15% over the forecast period 2023-2030. The generation of recombinant proteins, glycoproteins, tissue- and blood-derived products, medicinal devices, and monoclonal antibodies all depend on the viral clearance process. This is explained by the possibility of bacterial and fungal contamination, chemical contaminants, and viral contamination in these items. The market for viral safety practices is influenced by the viral clearance and assessment processes since they are important phases in product safety. The market growth is propelled by the increasing need for Viral Clearance, growing Demand for Specialty Drugs and rise in Research and Development Funding.
The expansion of the industry under study is further aided by increased financing for medicines across the United States. The American pharmaceutical sector annually develops a wide variety of novel drugs with important clinical benefits. Many of those drugs are expensive, which raises the expense of healthcare for both the federal government and the private sector. Through Operation Warp Speed and the Biomedical Advanced Research and Research Authority, the federal government in the United States funded USD 11 billion towards late-stage vaccine research and an increase in manufacturing capacity in 2020. Moreover, growth in demand in pharmaceutical and biotechnological industries and an increase in the number of mergers and acquisitions enhance the market opportunities over the years. However, the lack of Approval for Outsourcing of Preclinical Procedures stifles market growth throughout the forecast period of 2023-2030.
The key regions considered for the Global Viral Clearance Services Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. The North American region is currently dominating the viral clearance services market due to the presence of many pharmaceutical and biotech companies, growing government funding for research and development activities, and a well-established healthcare infrastructure. However, the Asia-Pacific region is expected to be the fastest-growing region in the viral clearance services market. The growth in this region can be attributed to the increasing demand for biopharmaceuticals, the growing number of Contract Research Organizations (CROs), and the increasing outsourcing of biopharmaceutical manufacturing to countries such as China and India
Major market players included in this report are:
- Charles River Laboratories, Inc.
- Labor Dr. Merk & Kollegen GmbH
- Merck KGaA
- Texcell SA
- WuXi AppTec
- Sartorius AG
- Eurofins Scientific
- Bioscience Laboratories
- Vironova AB
Recent Developments in the Market:
- In September 2022, Merck inaugurated a viral clearance (VC) lab as a part of the initial construction phase of its new EUR 29 million China Biologics Testing Centre.
- In April 2022, Abzena, a partner research organisation (PRO), =announced the launch of a biologics testing facility close to the company's biologics process development and manufacturing base in San Diego, California. Partners will have access to viral clearance studies, cell-based and PCR safety testing, and IND, IMPD, BLA, and MAA submissions through the facility.
Global Viral Clearance Services Market Report Scope:
- Historical Data: - 2020 - 2021
- Base Year for Estimation: - 2022
- Forecast period: - 2023-2030
- Report Coverage: - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
- Segments Covered: - Method, Application, End user, Region
- Regional Scope: - North America; Europe; Asia Pacific; Latin America; Middle East Africa
- Customization Scope: - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.
By Method:
- Viral Removal
- Viral Inactivation
By Application:
- Recombinant Proteins
- Tissue and Blood Derived Products
- Vaccines
- Other
By End User:
- Biopharmaceuticals
- Contract Research Organizations
- Academic Research Institutes
By Region:
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Spain
- Italy
- ROE
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- RoAPAC
- Latin America
- Brazil
- Mexico
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Table of Contents
Chapter 1. Executive Summary
- 1.1. Market Snapshot
- 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
- 1.2.1. Viral Clearance Services Market, by region, 2020-2030 (USD Billion)
- 1.2.2. Viral Clearance Services Market, by Method, 2020-2030 (USD Billion)
- 1.2.3. Viral Clearance Services Market, by Application, 2020-2030 (USD Billion)
- 1.2.4. Viral Clearance Services Market, by End User, 2020-2030 (USD Billion)
- 1.3. Key Trends
- 1.4. Estimation Methodology
- 1.5. Research Assumption
Chapter 2. Global Viral Clearance Services Market Definition and Scope
- 2.1. Objective of the Study
- 2.2. Market Definition & Scope
- 2.2.1. Industry Evolution
- 2.2.2. Scope of the Study
- 2.3. Years Considered for the Study
- 2.4. Currency Conversion Rates
Chapter 3. Global Viral Clearance Services Market Dynamics
- 3.1. Viral Clearance Services Market Impact Analysis (2020-2030)
- 3.1.1. Market Drivers
- 3.1.1.1. Increasing Need for Viral Clearance
- 3.1.1.2. Growing Demand for Specialty Drugs
- 3.1.1.3. Rise in Research and Development Funding
- 3.1.2. Market Challenges
- 3.1.2.1. Lack of Approval of Outsourcing of Preclinical Procedures
- 3.1.3. Market Opportunities
- 3.1.3.1. Growth in demand in pharmaceutical and biotechnological industries
- 3.1.3.2. Increase in number of mergers and acquisitions
Chapter 4. Global Viral Clearance Services Market Industry Analysis
- 4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.2. Porter's 5 Force Impact Analysis
- 4.3. PEST Analysis
- 4.3.1. Political
- 4.3.2. Economical
- 4.3.3. Social
- 4.3.4. Technological
- 4.3.5. Environmental
- 4.3.6. Legal
- 4.4. Top investment opportunity
- 4.5. Top winning strategies
- 4.6. COVID-19 Impact Analysis
- 4.7. Disruptive Trends
- 4.8. Industry Expert Perspective
- 4.9. Analyst Recommendation & Conclusion
Chapter 5. Global Viral Clearance Services Market, by Method
- 5.1. Market Snapshot
- 5.2. Global Viral Clearance Services Market by Method, Performance - Potential Analysis
- 5.3. Global Viral Clearance Services Market Estimates & Forecasts by Method 2020-2030 (USD Billion)
- 5.4. Viral Clearance Services Market, Sub Segment Analysis
- 5.4.1. Viral Removal
- 5.4.2. Viral Inactivation
Chapter 6. Global Viral Clearance Services Market, by Application
- 6.1. Market Snapshot
- 6.2. Global Viral Clearance Services Market by Application, Performance - Potential Analysis
- 6.3. Global Viral Clearance Services Market Estimates & Forecasts by Application 2020-2030 (USD Billion)
- 6.4. Viral Clearance Services Market, Sub Segment Analysis
- 6.4.1. Recombinant Proteins
- 6.4.2. Tissue and Blood Derived Products
- 6.4.3. Vaccines
- 6.4.4. Others
Chapter 7. Global Viral Clearance Services Market, by End User
- 7.1. Market Snapshot
- 7.2. Global Viral Clearance Services Market by End User, Performance - Potential Analysis
- 7.3. Global Viral Clearance Services Market Estimates & Forecasts by End User 2020-2030 (USD Billion)
- 7.4. Viral Clearance Services Market, Sub Segment Analysis
- 7.4.1. Biopharmaceuticals
- 7.4.2. Contract Research Organizations
- 7.4.3. Academic Research Institutes
Chapter 8. Global Viral Clearance Services Market, Regional Analysis
- 8.1. Top Leading Countries
- 8.2. Top Emerging Countries
- 8.3. Viral Clearance Services Market, Regional Market Snapshot
- 8.4. North America Viral Clearance Services Market
- 8.4.1. U.S. Viral Clearance Services Market
- 8.4.1.1. Method breakdown estimates & forecasts, 2020-2030
- 8.4.1.2. Application breakdown estimates & forecasts, 2020-2030
- 8.4.1.3. End User breakdown estimates & forecasts, 2020-2030
- 8.4.2. Canada Viral Clearance Services Market
- 8.5. Europe Viral Clearance Services Market Snapshot
- 8.5.1. U.K. Viral Clearance Services Market
- 8.5.2. Germany Viral Clearance Services Market
- 8.5.3. France Viral Clearance Services Market
- 8.5.4. Spain Viral Clearance Services Market
- 8.5.5. Italy Viral Clearance Services Market
- 8.5.6. Rest of Europe Viral Clearance Services Market
- 8.6. Asia-Pacific Viral Clearance Services Market Snapshot
- 8.6.1. China Viral Clearance Services Market
- 8.6.2. India Viral Clearance Services Market
- 8.6.3. Japan Viral Clearance Services Market
- 8.6.4. Australia Viral Clearance Services Market
- 8.6.5. South Korea Viral Clearance Services Market
- 8.6.6. Rest of Asia Pacific Viral Clearance Services Market
- 8.7. Latin America Viral Clearance Services Market Snapshot
- 8.7.1. Brazil Viral Clearance Services Market
- 8.7.2. Mexico Viral Clearance Services Market
- 8.8. Middle East & Africa Viral Clearance Service Market
- 8.8.1. Saudi Arabia Viral Clearance Service Market
- 8.8.2. South Africa Viral Clearance Service Market
- 8.8.3. Rest of Middle East & Africa Viral Clearance Service Market
Chapter 9. Competitive Intelligence
- 9.1. Key Company SWOT Analysis
- 9.1.1. Company 1
- 9.1.2. Company 2
- 9.1.3. Company 3
- 9.2. Top Market Strategies
- 9.3. Company Profiles
- 9.3.1. Vironova AB
- 9.3.1.1. Key Information
- 9.3.1.2. Overview
- 9.3.1.3. Financial (Subject to Data Availability)
- 9.3.1.4. Method Summary
- 9.3.1.5. Recent Developments
- 9.3.2. Charles River Laboratories, Inc.
- 9.3.3. Labor Dr. Merk & Kollegen GmbH
- 9.3.4. Merck KGaA
- 9.3.5. Texcell SA
- 9.3.6. WuXi AppTec
- 9.3.7. Sartorius AG
- 9.3.8. Eurofins Scientific
- 9.3.9. Bioscience Laboratories
Chapter 10. Research Process
- 10.1. Research Process
- 10.1.1. Data Mining
- 10.1.2. Analysis
- 10.1.3. Market Estimation
- 10.1.4. Validation
- 10.1.5. Publishing
- 10.2. Research Attributes
- 10.3. Research Assumption